Antibody-Drug Conjugates and Linker Engineering 2

• 1704 · PDF 针对不稳定的抗体药物偶联物连接子受控起始物料 BCN-OH 的纯度与含量 HPLC 方法开发 Method development of purity and assay HPLC method for unstable antibody-drug conjugate linker regulated starting material BCN-OH Yilin Hao, Yujie Guo, Jing Zhuang, Shijuan Xu, Lynn Wang, Xudong Wei, Gengcheng Jack Yang
• 1705 · PDF 抗体药物偶联物载荷-连接子常规色谱分析检测的兼容性研究 Compatibility study of routine chromatographic analytical testing of antibody-drug conjugate payload-linkers Tingting Xu, Yupei Deng, Xinsheng Yang, Lynn Wang, Jianqiang Li, Xudong Wei
• 1706 · PDF 一套整合的体外与体内综合策略用于抗体药物偶联物的开发 An integrate comprehensive in vitro and in vivo strategies for antibody drug conjugate development Ismahène Benzaid, Peggy Provent, Aurélie Durgeau, Didier Grillot, Marc Hillairet de Boisferon
• 1707 · PDF ZW191——一种差异化的FRalpha靶向拓扑异构酶I抗体药物偶联物，与标准治疗药物联用具有活性 ZW191 - a differentiated FRalpha-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs Sam Lawn, Andrea Hernández Rojas, Jodi Wong, Araba Sagoe-Wagner, Vincent Fung, Kurt Stahl, Ambroise Wu, Lemlem T. Degefie, Steve Seredick, Pranshul Chauhan, Raffaele Colombo, Jamie R. Rich, Stuart D. Barnscher, Paul A. Moore
• 1708 · PDF 新型DLL3 x B7H3双特异性ADC在临床前研究中展示出更优的疗效 Novel DLL3 x B7H3 bispecific ADC demonstrated superior efficacy in preclinical studies Sipeng Li, Chong Liu, Meijun Xiong, Yajun Sun, Zhongsheng Hu, Xinju Gao, Haibo He, Yanwen Feng, Zengyan Mu, Paul H. Song, Gang Qin
• 1709 · PDF BCG042：一种具有ADCC增强的有前景的抗LILRB4抗体在单核细胞性AML临床前模型中展示出更优疗效 BCG042: A promising anti-LILRB4 antibody with ADCC enhancement demonstrates superior efficacy in preclinical models of monocytic AML Jade Hsu, Peiran Li, Yanan Guo
• 1710 1710 ORM-1153：一种新型CD123靶向降解剂抗体偶联物，携带专有GSPT1降解载荷，用于治疗急性髓系白血病 ORM-1153: A novel CD123-targeting degrader antibody conjugate with proprietary GSPT1 degrading payload for the treatment of acute myeloid leukemia Dongki Choi, Adam Boutin, Jessica Alves, Sang Hyun Lee, Maysoun Shomali, Anna Skaletskaya, Hangyeol Jeong, MinSoo Kim, Da-Yeong Kim, Khuloud Takrouri, Qinsi Zheng, Nadia Cherkassky, Teresa Mako, Vineetkumar B. Patil, Olaf Christensen, YeonHee Yang, James Palacino
• 1711 · PDF GS002，一种具有靶向细胞毒递送和免疫检查点抑制的新型抗PD-L1 ADC GS002, a novel anti-PD-L1 ADC with targeted cytotoxic delivery and immune checkpoint inhibition Lin Jun, An Deqiang, Song Liwei, Zhu Hongju, Yuan Qiwei, Li Jianshi, Miao Zhongyi, Gao Zhen, Zhou Fang, Wang Xiaolei, Chen Tao, Zhuang Lu, Zhou Kaiyue, Yang Bo, Si Xinjuan, Hu Wenwen, Chang Genqiong, Xu Maosen, Liu Bin, Luo Shun
• 1712 · PDF PA289：一种同类首创的前药载荷，具有新型作用机制和良好的疗效/安全性特征 PA289: A first-in-class prodrug payload with a novel mechanism of action and favorable efficacy/safety profile Alicja Turska, Marc Lee, Bryony Moss, Yong Yi, Iris Britwum, Samuel Barton, Zoë Jukes, Toni Pringle, Adam Lodge, Justyna H. Mysliwy, Jutta Deckert, Robert J. Lutz
• 1713 · PDF STRO-006：一种整合素beta-6靶向ADC在临床前实体瘤中展示出良好的安全性特征和强效抗肿瘤活性 STRO-006: An Integrin beta-6-targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors Kshama A. Doshi, Stephanie Armstrong, Eunice Kim, Dan Shen, Sihong Zhou, Rhoneil Pena, Robert Yuan, Mark Armanini, Brian Vuillemenot, Xiaofan Li, Guifen Xu, Krishna Bajjuri, Miao Wen, Jeff Hanson, Cuong Tran, Amandeep Gakhal, GARRETT GROSS, Gang Yin, Werner Rubas, Genevive Hernandez, Daniel Calarese, Hans-Peter Gerber, Alice Yam
• 1714 1714 首创CHK1抑制剂抗体药物偶联物克服现有ADC载荷的局限性，为HER2阳性及TOP1抑制剂耐药肿瘤提供新选择 First-in-class CHK1 inhibitor antibody-drug conjugate overcomes limitations of current ADC payloads and provides a new option for HER2-positive and TOP1 inhibitor-resistant tumors Thanos D. Halazonetis, Giacomo G. Rossetti, Daniela Carraturo, Michalis Petropoulos, Camilla Trugenberger, Theodoros Rampias, Dennis Gillingham
• 1715 · PDF JS212，一种靶向EGFR和HER3的新型双特异性ADC，在临床前评估中展现出优越且广谱的抗肿瘤活性 JS212, a novel bispecific ADC targeting EGFR and HER3, demonstrates superior and broad antitumor activity in preclinical evaluation Wenli Shi, Ning Song, Qiang Fu, Li Ye, Aikun Xia, Mingxing Yang, Jiaming Wang, Xuan Wu, Yue Deng, Yanghua Xu, Xin Wang, Honglin He, Yuyuan Yan, Ziyang Zhong
• 1716 · PDF AT06是一种靶向DLL3和SEZ6的双特异性抗体药物偶联物，在小细胞肺癌（SCLC）模型中具有强效活性 AT06 is a bispecific antibody drug conjugate targeting DLL3 and SEZ6 with potent activity in small cell lung cancer (SCLC) models Bin Zou, Bryan K. S. Yeung, Nannan Lang
• 1717 · PDF SCR-A014，一种靶向B7H3和DLL3用于SCLC治疗的新型双特异性ADC，展现出强效的抗肿瘤疗效 SCR-A014, a novel bispecific ADC targeting B7H3 and DLL3 for SCLC therapy, exhibits potent anti-tumor efficacy Guangcun Cheng, Yayuan Fu, Jiajing Wang, Shuai Wang, Guimei Yang, Chunlei Xia, Xiaoxing Huang, Renhong Tang
• 1718 · PDF RT023，一种在结直肠癌（CRC）中靶向CEACAM5/EGFR的首创双特异性抗体药物偶联物（ADC） RT023, a first-in-class CEACAM5/EGFR targeted bispecific antibody drug conjugate (ADC) in colorectal cancer (CRC) Shuting Huang, Lulu Zhou, Jingjing Cao, Lingli Bi, Qiang Fu, Xuan Wu, Aikun Xia, Jiaming Wang, Yue Deng, Yanghua Xu, Xin Wang, Wenli Shi, Honglin He, Yuyuan Yan, Ziyang Zhong
• 1720 · PDF BCG039（一种Nectin-4×TROP2双特异性ADC）在尿路上皮癌及其他实体瘤模型中的临床前研究 Preclinical study of BCG039, a Nectin-4×TROP2 bispecific ADC, in urothelial carcinoma and other solid tumor models Frank An, Liu Yang, Chengzhang Shang, Junlan Han, Yi Yang, Frank An
• 1721 · PDF BCG041：一种靶向B7-H3和MUC1近膜区的首创双特异性ADC，具有优越的抗肿瘤活性 BCG041: A first-in-class bispecific ADC targeting B7-H3 and the proximal membrane region of MUC1 with superior antitumor activity Icy Niu, Peiran Li, Ying Zhu, Yanan Guo
• 1722 1722 基于改进的异源二聚化平台和精确控制的新型载荷偶联，利用高度可开发的双特异性抗体药物偶联物对异质性肿瘤进行最优靶向 Optimal targeting of heterogeneous tumors using highly developable bispecific antibody drug conjugates based on an improved heterodimerization platform and precisely controlled conjugation of a novel payload Dongsop Lee, Younggyu Kong, Seong-Hyun Park, Hyeonseok Jin, Aera Lee, Haerynn Chung, Jungwoo Kim, Jinhoon Jung, Haedueok Jung, Yunjung Um, Youngjee Jeong, Su jin Jung, Haneol Kim, Kyoung-Ho Pyo, Hyungseok Choi, Mi-Kyung Kim
• 1723 1723 将临床阶段的 GlycoConnect® 技术应用于双特异性抗体，可获得优于随机偶联 bsADC 的双特异性 ADC Application of clinical stage GlycoConnect® technology to bispecific antibodies yields improved bispecific ADCs in comparison to randomly conjugated bsADCs Lianne Lelieveldt, Nazli Hilal Turkmen, Kinneret Rozales, Maya Wadmany, Anna Kaliakatsou, Floris van Delft, Anette Sommer
• 1724 · PDF NEOK001（ABL206）：一种同类首创的 B7-H3xROR1 双特异性 ADC，显示出增强的疗效和良好的耐受性 NEOK001 (ABL206): A first in class B7-H3xROR1 bispecific ADC demonstrated enhanced efficacy and promising tolerability Min Ji Ko, Junga Kwon, Suyoun Lee, Juhee Kim, Ilhwan Ryu, Junyoung Kim, JaeHyun Eom, Byeong Min Yoo, Hyeon Ji Park, Yong-Gyu Son, Donghoon Yeom, Arim Seo, Byungje Sung, Jinwon Jung, Jinhyung Ahn, Weon-Kyoo You, Sang Hoon Lee
• 1725 1725 EpiTAC 双特异性降解剂 ADC 的双重模式将 c-MET 降解与细胞毒性载荷递送相结合，以克服当前 c-MET 靶向疗法的局限性 Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload delivery to overcome limitations of current c-MET-targeted therapies Lisa Marshall, Jonathan Sitrin, Kenneth Ng, Shruti Yadav, May Dayao, Hai Tran, Josef Gramespacher, Jacob Cohen, Kimberly Hoi, Zhong Huang, Noah Solomon, John Coan, Andy Goodrich, Adison McLaggan, Sarah Yan, Brian Hillier, Danica Manalo-Hebert, Lichao Zhang, Maia Vinogradova, Isaac J. Rondon, Shyra J. Gardai
• 1726 · PDF NEOK002（ABL209）：重新设计具有良好抗肿瘤活性和增强治疗窗口的 EGFRxMUC1 双特异性 TOP1i ADC NEOK002 (ABL209): Redesigning an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window Bora Lee, Hyeon Ji Park, Byeong Min Yoo, Hangil Kim, Junyoung Kim, Arim Seo, Youngeun Hong, Donghoon Yeom, Yong-Gyu Son, Jaehyun Eom, Byungje Sung, Jinhyung Ahn, Jinwon Jung, Weon-Kyoo You, Sang Hoon Lee
• 1727 · PDF 通过 eKiH 工程化双特异性 ADC 双重靶向 HER2 和 AXL 以克服实体瘤中的耐药性 Dual targeting of HER2 and AXL by an eKiH-engineered bispecific ADC to overcome resistance in solid tumors Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
• 1728 · PDF 用 eKiH 工程化 CLDN18.2×HER2 双特异性 ADC 克服胃癌中的靶点异质性 Overcoming target heterogeneity in gastric cancer with an eKiH-engineered CLDN18.2×HER2 bispecific ADC Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
• 1729 · PDF OBI-904，一种新一代靶向 nectin-4 的 exatecan ADC，显示出增强的细胞毒性并克服 enfortumab vedotin 耐药 OBI-904, a next-generation nectin-4-targeting exatecan ADC, demonstrates enhanced cytotoxicity and overcomes enfortumab vedotin resistance Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen
• 1730 · PDF 引导-效应 bsADC：驱动共内吞以增强载荷递送 Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen
• 1731 · PDF 亲水性增强的连接子技术助力实现位点特异性降解剂-抗体偶联物，兼具更优稳定性与更强活性 Hydrophilicity-enhanced linker technology enables site-specific degrader-antibody conjugates with improved stability and enhanced activity Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang

在会议检索中浏览本分会场